What Just Changed — and Why It Matters
On April 15, 2026, the FDA published its most consequential 503A category revision in years. In a single update, twelve peptide-based bulk drug substances are being removed from Category 2 — the list of compounds designated as raising significant safety concerns — effective seven calendar days from publication.
For licensed physicians who work with compounding pharmacies, the distinction matters. Category 2 status has effectively placed these substances in regulatory limbo, creating uncertainty for both prescribers and 503A pharmacies. This update initiates a formal path forward: the FDA has announced scheduled Pharmacy Compounding Advisory Committee (PCAC) consultations for each of the affected substances through mid-2027, signaling a structured, science-based review process rather than continued indefinite restriction.
This Is a Process Step, Not a Final Clearance
Removal from Category 2 does not mean these substances have been evaluated and approved for the 503A bulks list. It means the formal scientific review process — through a publicly accountable advisory committee — is now formally scheduled. Prescribers should maintain appropriate clinical documentation and consult with their compounding pharmacy partner about current dispensing status.
